Braun Stacey Associates
CL icon

Braun Stacey Associates’s Colgate-Palmolive CL Stock Holding History

Braun Stacey Associates’s Portfolio CL Stock Details CL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.16M Sell
60,535
-4,990
-8% -$452K 0.15% 89
2026
Q2 		$6.01M Sell
65,525
-170,340
-72% -$14.9M 0.17% 88
2026
Q1 		$20.1M Buy
235,865
+12,075
+5% +$1.08M 0.67% 67
2025
Q4 		$17.7M Sell
223,790
-9,343
-4% -$733K 0.57% 75
2025
Q3 		$18.6M Sell
233,133
-4,915
-2% -$419K 0.61% 75
2025
Q2 		$21.6M Sell
238,048
-10,079
-4% -$920K 0.78% 56
2025
Q1 		$23.2M Sell
248,127
-2,660
-1% -$238K 0.95% 43
2024
Q4 		$22.8M Buy
250,787
+19,967
+9% +$1.91M 0.85% 45
2024
Q3 		$24M Buy
+230,820
New +$23.5M 0.91% 41
2018
Q2 		– Sell
-73,345
Closed -$5.26M – 122
2018
Q1 		$5.26M Sell
73,345
-20,645
-22% -$1.49M 0.36% 96
2017
Q4 		$7.09M Buy
93,990
+26,335
+39% +$1.92M 0.48% 91
2017
Q3 		$4.93M Buy
67,655
+653
+1% +$47.1K 0.34% 97
2017
Q2 		$4.97M Buy
67,002
+2,472
+4% +$184K 0.32% 98
2017
Q1 		$4.72M Sell
64,530
-17,900
-22% -$1.25M 0.3% 101
2016
Q4 		$5.39M Buy
82,430
+17,270
+27% +$1.18M 0.35% 102
2016
Q3 		$4.83M Buy
65,160
+920
+1% +$68K 0.31% 103
2016
Q2 		$4.7M Buy
64,240
+2,060
+3% +$147K 0.3% 101
2016
Q1 		$4.39M Sell
62,180
-1,115
-2% -$74.2K 0.29% 100
2015
Q4 		$4.22M Buy
63,295
+5,400
+9% +$359K 0.27% 98
2015
Q3 		$3.67M Sell
57,895
-105,210
-65% -$6.87M 0.25% 99
2015
Q2 		$10.7M Buy
163,105
+50,820
+45% +$3.45M 0.45% 93
2015
Q1 		$7.79M Sell
112,285
-94,785
-46% -$6.55M 0.46% 95
2014
Q4 		$14.3M Sell
207,070
-25,400
-11% -$1.72M 0.87% 73
2014
Q3 		$15.2M Buy
232,470
+11,660
+5% +$769K 0.94% 61
2014
Q2 		$15.1M Buy
220,810
+26,215
+13% +$1.76M 0.9% 66
2014
Q1 		$12.6M Buy
194,595
+2,730
+1% +$172K 0.74% 79
2013
Q4 		$12.5M Sell
191,865
-10,250
-5% -$656K 0.72% 81
2013
Q3 		$12M Buy
202,115
+14,160
+8% +$839K 0.74% 81
2013
Q2 		$10.8M Buy
+187,955
New +$11.2M 0.68% 89

Other funds holding CL

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Braun Stacey Associates's CL Position: Q3 2026 in Review

Braun Stacey Associates reduced its Colgate-Palmolive (CL) stake by 7.6% in Q3 2026, selling an estimated $452K and leaving 60,535 shares worth $5.16M. The position accounts for 0.15% of the portfolio, ranked #89.

Braun Stacey Associates first reported a position in CL in Q2 2013 and has held it in 29 quarters since. The position peaked at $24M in Q3 2024. 1,712 funds tracked by Wall St. Rank hold CL as of Q3 2026.

  • Braun Stacey Associates held 60,535 shares of Colgate-Palmolive worth $5.16M as of Q3 2026.
  • Braun Stacey Associates sold 4,990 Colgate-Palmolive shares in Q3 2026, an estimated $452K.
  • Colgate-Palmolive made up 0.15% of Braun Stacey Associates's portfolio in Q3 2026, its #89 holding.
  • Braun Stacey Associates first reported a position in Colgate-Palmolive in Q2 2013 and has held it in 29 quarters since.
  • Braun Stacey Associates's Colgate-Palmolive position peaked at $24M in Q3 2024.
  • 1,712 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q3 2026.

Based on Braun Stacey Associates's 13F filing for Q3 2026, filed 19 Oct 2026.